Sciele Pharma Inc. (NASDAQ: SCRX), a specialty pharmaceutical company, closed at $26.54. SCRX has a Sular line extension PDUFA on November 2. Roth Capital Partners has a Buy rating and $33 price target on SCRX. Roth says, "Pipeline strong, future looks bright, SCRX has eight products in different stages. One recently approved (Fenofibrate), two under review at the FDA (head lice and "new sular"), and five in Pivotal Ph 3 trials." SCRX November option implied volatility of 59 is above its 26-week average of 37 according to Track Data, suggesting larger risk.
MicroStrategy Inc. (NASDAQ: MSTR) is recently up $11.43 to $98 in pre-open trading. MSTR reported 3Q EPS of $1.51 verses consensus estimates of $1.11. Cowen says, "despite the strong license performance in the Q, the company is suffering from negative license growth year to date off a weak comp." MSTR over all option implied volatility of 49 is 42 according to Track Data, suggesting larger risk.
Daily options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.
Closing Bell: Can't go up every day (BAC, HE, HPW, COMS, BRCD, WMT, AMD)
Wal-Mart grows profit and cash flow in Q3, but comps still ailing
Chasing Value: Ten stocks for 2010 -- Part 2
